Study on Intismeran (V940) With or Without Pembrolizumab for High-Risk Stage I Non-Small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with Stage I non-small cell lung cancer (NSCLC) with specific high-risk features like tumor size over 2 cm or certain types of tissue invasion.
• Have had the primary lung cancer completely removed by surgery.
• Have not received any other treatments like chemotherapy or radiotherapy for the current lung cancer.
• Provided a tissue sample from recent surgery and a blood sample.
• If HIV-positive, must have well-controlled HIV on antiretroviral therapy.
• If hepatitis B positive, must have been on antiviral therapy for at least 4 weeks with undetectable viral load.
• If previously infected with hepatitis C, must have undetectable viral load at screening.

Exclusion Criteria

• Diagnosed with small cell lung cancer or certain other types of lung cancer.
• Have had significant heart problems in the past year, like heart surgery or heart attacks.
• HIV-positive participants with a history of certain cancers like Kaposi's sarcoma.
• Have another cancer that is progressing or needed treatment in the last 3 years.
• Have an active autoimmune disease needing treatment in the past 2 years, except for hormone replacement.
• Have a history of lung disease requiring steroids or currently have lung disease.
• Have an active infection needing treatment, except those allowed by the study.
• Have had a stem cell or organ transplant.
• Have not fully recovered from major surgery or have ongoing surgical issues.